© Drug Hunter Inc. 2018-2023
Home > FT-2102 (olutasidenib)
allosteric mutant-selective IDH1 inhibitor
oral, in clinical development
from SBDD of prior mIDH inhibitor
J. Med. Chem. 2020, 63, 1612-1623
FORMA Therapeutics, Watertown, MA
FT-2102 (olutsidenib) (FORMA oral allosteric mutant-selective IDH1 inhibitor clinical candidate)
Drug Hunter is commited to helping industry innovators make informed decisions. Premium members have access to our library of the latest stories in science, written by scientists.
Request a trial to access insights powering the pros in our industry.
Molecules of the Month
Molecule of the Year